Cellectar reports Phase 1 study publication supports iopofosine I-131 potential in relapsed multiple myeloma

Cellectar Biosciences

CLRB

0.00

Cellectar BioSciences reported publication of Phase 1 results for iopofosine I 131 plus low-dose dexamethasone in relapsed/refractory multiple myeloma.
In 26 efficacy-evaluable patients, 84.6% achieved stable disease or better; overall response rate was 15.4% with four partial responses.
Among patients receiving at least 60 mCi (n=10), overall response rate was 30%, suggesting higher activity at higher total administered doses.
Safety profile was described as manageable, with adverse events mainly predictable, reversible cytopenias; no new safety signals were identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150730PRIMZONEFULLFEED9762056) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.